These findings are in agreement with Jankowska and colleagues [4] and Coutinho and colleagues [6], who reported TET2 downregulation in 16 patients with MDS/myeloproliferative neoplasms and in 12 patients with pediatric MDS, respectively, regardless of TET2 mutational status. Here, TET2 is linked to myelodysplastic syndrome.